Literature DB >> 29149943

Endocrine and Metabolic Alterations in Sepsis and Implications for Treatment.

Catherine Ingels1, Jan Gunst1, Greet Van den Berghe2.   

Abstract

Sepsis induces profound neuroendocrine and metabolic alterations. During the acute phase, the neuroendocrine changes are directed toward restoration of homeostasis, and also limit unnecessary energy consumption in the setting of restricted nutrient availability. Such changes are probably adaptive. In patients not recovering quickly, a prolonged critically ill phase may ensue, with different neuroendocrine changes, which may represent a maladaptive response. Whether stress hyperglycemia should be aggressively treated or tolerated remains a matter of debate. Until new evidence from randomized controlled trials becomes available, preventing severe hyperglycemia is recommended. Evidence supports withholding parenteral nutrition in the acute phase of sepsis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortisol; Endocrine; Growth hormone; Hyperglycemia; Insulin; Nutrition; Sepsis; Thyroid hormone

Mesh:

Year:  2017        PMID: 29149943     DOI: 10.1016/j.ccc.2017.08.006

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  14 in total

1.  Use of Organ Dysfunction as a Primary Outcome Variable Following Cecal Ligation and Puncture: Recommendations for Future Studies.

Authors:  Mabel N Abraham; Alexander P Kelly; Ariel B Brandwein; Tiago D Fernandes; Daniel E Leisman; Matthew D Taylor; Mariana R Brewer; Christine A Capone; Clifford S Deutschman
Journal:  Shock       Date:  2020-08       Impact factor: 3.454

Review 2.  The Role of Adipose Tissue and Adipokines in Sepsis: Inflammatory and Metabolic Considerations, and the Obesity Paradox.

Authors:  Irene Karampela; Gerasimos Socrates Christodoulatos; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2019-12

3.  ENDOCRINE DISTURBANCES INDUCED BY LOW-DOSE ORGANOPHOSPHATE EXPOSURE IN MALE WISTAR RATS.

Authors:  C Cobilinschi; R C Tincu; A E Băetu; C O Deaconu; A Totan; A Rusu; P T Neagu; I M Grințescu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

4.  Thyroid hormone disorders: a predictor of mortality in patients with septic shock defined by Sepsis-3?

Authors:  Yan-Cun Liu; Tian-Yu Jiang; Zhen-Sen Chen; An-Long Qi; Yu-Lei Gao; Shi-Xin Li; Mu-Ming Yu; Yan-Fen Chai; Song-Tao Shou
Journal:  Intern Emerg Med       Date:  2020-11-05       Impact factor: 3.397

Review 5.  PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis.

Authors:  Weronika Wasyluk; Agnieszka Zwolak
Journal:  J Inflamm Res       Date:  2021-05-06

6.  Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury.

Authors:  Daniel E Leisman; Tiago D Fernandes; Vanesa Bijol; Mabel N Abraham; Jake R Lehman; Matthew D Taylor; Christine Capone; Omar Yaipan; Rinaldo Bellomo; Clifford S Deutschman
Journal:  Kidney Int       Date:  2020-08-31       Impact factor: 10.612

Review 7.  Sepsis as a Pan-Endocrine Illness-Endocrine Disorders in Septic Patients.

Authors:  Weronika Wasyluk; Martyna Wasyluk; Agnieszka Zwolak
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

Review 8.  The Surviving Sepsis Campaign: research priorities for the administration, epidemiology, scoring and identification of sepsis.

Authors:  Mark E Nunnally; Ricard Ferrer; Greg S Martin; Ignacio Martin-Loeches; Flavia R Machado; Daniel De Backer; Craig M Coopersmith; Clifford S Deutschman
Journal:  Intensive Care Med Exp       Date:  2021-07-02

9.  Interleukin-2 Transiently Inhibits Pulsatile Growth Hormone Secretion in Young but not Older Healthy Men.

Authors:  Ferdinand Roelfsema; Rebecca Yang; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

Review 10.  Sepsis therapies: learning from 30 years of failure of translational research to propose new leads.

Authors:  Jean-Marc Cavaillon; Mervyn Singer; Tomasz Skirecki
Journal:  EMBO Mol Med       Date:  2020-03-16       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.